Companies › Kind Pharmaceuticals
2 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Genitourinary, Hematology, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AND017 HIF-1α stabilizer | HIF1A | Phase 3 | Anemia Due to Chronic Kidney Disease; Myelodysplastic Syndromes; β -Thalassemia | Dec 2026 |
| AND019 | – | Phase 1 | Advanced or Metastatic Breast Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05187832 | AND019 | Phase 1 | Advanced or Metastatic Breast Cancer | Oncology | Nov 2026 |
| NCT07487727 | AND017 | Phase 3 | Anemia Due to Chronic Kidney Disease | Genitourinary | Dec 2026 |
| NCT06304103 | AND017 | Phase 2 | Myelodysplastic Syndromes | Hematology | Dec 2026 |
| NCT06302491 | AND017 | Phase 2 | β -Thalassemia | Hematology | Dec 2026 |
| NCT07494409 | AND017 | Phase 3 | Anemia Due to Chronic Kidney Disease | Genitourinary | Apr 2027 |
Chengdu Suncadia Medicine Apellis Pharmaceuticals Shenzhen Kangzhe Biotechnology Biocity Biopharmaceutics Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.